Zoledronic acid in the management of metastatic bone disease

Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Moreover, in vivo preclinical and preliminary clinical data suggest that bisphosphonates may prevent cancer treatment-induced bone loss and the onset of malignant bone disease in patients with early-stage cancer. This comprehensive review critically reports the several preclinical evidences of action of bisphosphonates on osteoclasts, lymphocytes and tumour cells. In addition, all the clinical trials evaluating the effects of principal bisphosphonates on skeletal disease progression in patients with breast cancer, prostate cancer, non-small cell lung cancer and other cancers have been reported. Of the available bisphosphonates, intravenous zoledronic acid has demonstrated the broadest clinical activity and is actually approved for the treatment of bone metastases from any solid tumour in many countries. Renal safety is an important consideration for oncologists who are treating patients with bisphosphonates. This issue and the other topics relating to the safety of bisphosphonates are discussed in this review.

[1]  E. Waclawski.  Osteonecrosis of the jaw and bisphosphonates , 2006, BMJ : British Medical Journal.

[2]  S. Verma,et al.  Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Cameron,et al.  Ibandronate: its role in metastatic breast cancer. , 2006, The oncologist.

[4]  J. Berenson,et al.  Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Steger,et al.  Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Fizazi,et al.  A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Stiff,et al.  Management of the adverse effects associated with intravenous bisphosphonates. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  L. Elting,et al.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. , 2006, The Lancet. Oncology.

[9]  J. Kalmar,et al.  Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws , 2006, Annals of Internal Medicine.

[10]  A. Brufsky.  Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. , 2006, Seminars in oncology.

[11]  M. Marra,et al.  Emerging anti-cancer molecular mechanisms of aminobisphosphonates. , 2006, Endocrine-related cancer.

[12]  S. Rivkin.  Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The swog trial , 2006 .

[13]  M. Lichinitser,et al.  Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Comparative bone turnover marker and safety data , 2006 .

[14]  P. Barrett-Lee,et al.  Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI zice trial , 2006 .

[15]  B. Abrahamsen,et al.  Technology evaluation: denosumab, Amgen. , 2005, Current opinion in molecular therapeutics.

[16]  M. J. González‐Fernández,et al.  [Pamidronate and uveitis]. , 2005, Medicina clinica.

[17]  Jacques P. Brown,et al.  Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. , 2005, The New England journal of medicine.

[18]  D. Peterson,et al.  Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone , 2005, Cancer.

[19]  J. Beilin,et al.  Profound hypocalcaemia after zoledronic acid treatment , 2005, The Medical journal of Australia.

[20]  T. Tanvetyanon.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2005, Cancer.

[21]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  C. Scully,et al.  Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[23]  J. Durnian,et al.  Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy , 2005, Eye.

[24]  Richard Pazdur,et al.  Assessing Tumor-Related Signs and Symptoms to Support Cancer Drug Approval , 2004, Journal of biopharmaceutical statistics.

[25]  L. Rosen,et al.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion , 2004, Cancer.

[26]  M. Schuster,et al.  Oral Cavity Avascular Bone Necrosis - a Newly Recognized Complication of Intravenous (IV) Bisphosphonate Therapy in Cancer Patients. , 2004 .

[27]  R. Coleman.  Bisphosphonates: clinical experience. , 2004, The oncologist.

[28]  A. Lipton.  Toward new horizons: the future of bisphosphonate therapy. , 2004, The oncologist.

[29]  M. Greenberg.  Intravenous bisphosphonates and osteonecrosis. , 2004, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[30]  S. Lichtman,et al.  Renal dysfunction associated with bisphosphonate use: Retrospective analysis of 293 patients with respect to age and other clinical characteristics. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Glorieux,et al.  Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. , 2004, Bone.

[32]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[33]  Janet E Brown,et al.  The role of bisphosphonates in breast and prostate cancers. , 2004, Endocrine-related cancer.

[34]  D. Tripathy,et al.  Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies , 2004, British Journal of Cancer.

[35]  W. Fraser,et al.  Severe hypocalcaemia after being given intravenous bisphosphonate , 2004, BMJ : British Medical Journal.

[36]  F. Saad,et al.  615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases , 2004 .

[37]  A. Goss,et al.  Bisphosphonates and avascular necrosis of the jaws. , 2003, Australian dental journal.

[38]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Beitz,et al.  Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.

[40]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[41]  B. Vincenzi,et al.  The antineoplastic role of bisphosphonates: from basic research to clinical evidence. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[43]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[44]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  P. Subramanian,et al.  Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. , 2003, Archives of ophthalmology.

[46]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  T. J. Rosenberg,et al.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[48]  P. Reimer,et al.  Gammadelta T cells for immune therapy of patients with lymphoid malignancies. , 2003, Blood.

[49]  C. Maxwell,et al.  Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. , 2003, Clinical journal of oncology nursing.

[50]  P. Fine,et al.  Toxic acute tubular necrosis following treatment with zoledronate (Zometa). , 2003, Kidney international.

[51]  A. Goss,et al.  Current concepts of the management of dental extractions for patients taking warfarin. , 2003, Australian dental journal.

[52]  S. Fishbane.  Safety in iron management. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  David Roth,et al.  Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  C. Rosen,et al.  Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. , 2003, The New England journal of medicine.

[55]  Richard Pazdur,et al.  End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Frederick W. Fraunfelder,et al.  Scleritis and other ocular side effects associated with pamidronate disodium. , 2003, American journal of ophthalmology.

[57]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[58]  P. Clézardin.  The antitumor potential of bisphosphonates. , 2002, Seminars in oncology.

[59]  H. Goldschmidt,et al.  Bisphosphonates in multiple myeloma. , 2002, The Cochrane database of systematic reviews.

[60]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[61]  B. Hillner,et al.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Glatt,et al.  Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). , 2002, Journal of medicinal chemistry.

[63]  L. Demers,et al.  Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  F. Saad,et al.  The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.

[65]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[66]  P. Beuzeboc,et al.  Essai comparatif randomisé en double aveugle clodronate oral 1 600 mg/j versus placebo chez des patientes avec métastases osseuses de cancer du sein , 2001 .

[67]  R. Kyle,et al.  Update on the treatment of multiple myeloma. , 2001, The oncologist.

[68]  R E Coleman,et al.  Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases , 2001, Cancer.

[69]  J. Jonklaas,et al.  Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism , 2001, Endocrine.

[70]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  B. Hillner,et al.  American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .

[72]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[73]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[74]  D. Thiebaud,et al.  Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte Subpopulations , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  M. Pecherstorfer,et al.  Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy , 1999, Drug safety.

[76]  E. Pieterman,et al.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.

[77]  M. Groenvold,et al.  Oral clodronate in breast cancer patients with bone metastases: a randomized study , 1999, Journal of internal medicine.

[78]  C. Rudenstam,et al.  Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. , 1999, Acta oncologica.

[79]  C. Löwik,et al.  The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen‐Containing Bisphosphonates , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  M. Wilhelm,et al.  Gamma/delta T-cell stimulation by pamidronate. , 1999, The New England journal of medicine.

[81]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Dunn,et al.  A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma , 1998, British journal of haematology.

[84]  S. Nilsson,et al.  The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. , 1997, Anticancer research.

[85]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[86]  S. Mercadante.  Malignant bone pain: pathophysiology and treatment , 1996, Pain.

[87]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[88]  J. Bonneterre,et al.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  G. Blackburn,et al.  Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. , 1996, Biochemical and biophysical research communications.

[90]  I. Constable,et al.  Iritis following intravenous pamidronate. , 1996, Australian and New Zealand journal of medicine.

[91]  A. Crisp,et al.  Pamidronate and uveitis. , 1995, British journal of rheumatology.

[92]  H. Band,et al.  V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. , 1995, Journal of immunology.

[93]  M. Williamson,et al.  Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. , 1994, The Biochemical journal.

[94]  F. Fraunfelder,et al.  Pamidronate disodium and possible ocular adverse drug reactions. , 1994, American journal of ophthalmology.

[95]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[96]  B. Grosbois,et al.  Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myélome (GERM). , 1993, The European journal of medicine.

[97]  T. Tammela,et al.  Effect of oral clodronate on bone pain , 1992, International Urology and Nephrology.

[98]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[99]  S. Eto,et al.  [Hypercalcemia in malignancy]. , 1991, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[100]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  R. Demars,et al.  Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. , 1990, Science.

[102]  M. Sato,et al.  Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[103]  P. Eggli,et al.  Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat , 1986, Calcified Tissue International.

[104]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[105]  H. Shinoda,et al.  Structure-activity relationships of various bisphosphonates , 2006, Calcified Tissue International.

[106]  A. Sebba,et al.  Optimizing Administration of Bisphosphonates in Women with Postmenopausal Osteoporosis , 2005, Treatments in endocrinology.

[107]  J. Berenson.  Recommendations for zoledronic acid treatment of patients with bone metastases. , 2005, The oncologist.

[108]  C. Estilo,et al.  Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Y. Ohashi,et al.  A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Adachi,et al.  Corticosteroid-induced osteoporosis: a guide to optimum management. , 2002, Treatments in endocrinology.

[111]  L. Mauriac,et al.  [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. , 2001, Bulletin du cancer.

[112]  H. Goldschmidt,et al.  Bisphosphonates in multiple myeloma. , 2001, The Cochrane database of systematic reviews.

[113]  G. Besser,et al.  Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

[114]  J. Adachi,et al.  Corticosteroid-Induced Osteoporosis , 1998, Journal of the American Medical Women's Association.

[115]  G. Libero.  Sentinel function of broadly reactive human γδ T cells , 1997 .

[116]  J. Risteli,et al.  Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer. , 1997, British Journal of Cancer.

[117]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[118]  T. Tammela,et al.  The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. , 1994, Annales chirurgiae et gynaecologiae.

[119]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  J. Bevan,et al.  Antiresorptive dose-response relationships across three generations of bisphosphonates. , 1989, Drugs under experimental and clinical research.

[121]  J. Smith,et al.  Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. , 1989, The Journal of urology.

[122]  H. Tony,et al.  Stimulation of gd T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma , 2022 .